Breakthrough study reveals Delcath Systems’ therapy doubles survival for uveal melanoma patients
Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering company in interventional oncology, has announced promising results from a recent independent study evaluating its liver-directed therapy for ... Read More
SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee's Pharmaceutical, has announced the ... Read More
FDA approves Eisai and Merck’s Lenvima for first-line treatment of liver cancer
In a significant development for cancer treatment, Eisai and Merck have announced that the U.S. Food and Drug Administration (FDA) has approved Lenvima (lenvatinib) for ... Read More